Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition

Polo-like kinase 1 (Plk1) is considered an attractive target for anticancer therapy. Over the years, studies on the noncatalytic polo-box domain (PBD) of Plk1 have raised the expectation of generating highly specific protein–protein interaction inhibitors. However, the molecular nature of the canoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jung-Eun, Kirsch, Klara, Lee, Hobin, Oliva, Paola, Ahn, Jong Il, Ravishankar, Harsha, Zeng, Yan, Fox, Stephen D., Kirby, Samuel A., Badhwar, Pooja, Andresson, Thorkell, Jacobson, Kenneth A., Lee, Kyung S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Physical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629583/
https://www.ncbi.nlm.nih.gov/pubmed/37603740
http://dx.doi.org/10.1073/pnas.2305037120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629583/
https://www.ncbi.nlm.nih.gov/pubmed/37603740
http://dx.doi.org/10.1073/pnas.2305037120

Ejemplares similares